Spinal delivery of sufentanil, alfentanil, and morphine in dogs

Physiologic and toxicologic investigations

M. B. Sabbe, Marjorie Grafe, E. Mjanger, P. J. Tiseo, H. F. Hill, T. L. Yaksh

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: This study examines the behavioral effects and potential neurotoxicity of sufentanil, alfentanil, and morphine after chronic daily epidural (15 day) and intrathecal (28-day) administration in dogs. Methods: Dogs were chronically implanted with a lumbar intrathecal or epidural catheter and received daily injections for 28 or 15 days, respectively, of saline or one of three μ agonists: sufentanil (intrathecal 5, 25, or 50 μg/0.5 ml; epidural 10, 50, or 100 μg/2.0 ml), alfentanil (intrathecal 40 or 400 μg/0.5 ml; epidural 80 or 800 μg/2.0 ml), or morphine (intrathecal 0.5 or 5 mg/0.5 ml; epidural 1 or 10 mg/2.0 ml). Dogs were examined for antinociception (skin twitch) and neurobehavioral changes. When the animals were killed, cisternal cerebrospinal fluid was taken for clinical chemistry, and after perfusion fixation, spinal cord tissue was taken for histologic analysis. Results: Bolus intrathecal and epidural injections of sufentanil, alfentanil and morphine produced dose dependent antinociception, bradycardia, an initial tachypnea followed by a decrease in respiratory rate, hypothermia and somnolence. The order of potency was sufentanil > alfentanil > morphine on all measures. Over the extended period of drug delivery, a loss of response (tolerance) was observed on all measures. No abnormal morphologic or histologic effects were found when comparing the drug and dose groups. An inflammatory reaction secondary to the catheter was found in all animals intrathecal, but not epidural, catheters resulted in significant increases in cerebrospinal fluid protein and cell counts in vehicle animals. Values in drug treated animals did not differ significantly from the respective vehicle controls. A rapid systemic redistribution of all three drugs were observed. No differences were found in the pharmacokinetic parameters measured at day 1 and at the day of killing for any route. Conclusions: This large-animal model demonstrates the expected pharmacologic potency of these three agents and tolerance development. Based on cerebrospinal fluid and systematic histopathologic analyses, these three spinally administered agents showed no evidence of neurotoxicity over the range of doses/concentrations employed when given by the intrathecal or epidural route as compared to vehicle controls. Consideration of the toxicokinetics in this canine model suggests that it provides an appropriate test of the safety of these agents in concentrations which exceed those employed for daily intermittent epidural and intrathecal drug delivery in humans.

Original languageEnglish (US)
Pages (from-to)899-920
Number of pages22
JournalAnesthesiology
Volume81
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Sufentanil
Alfentanil
Morphine
Dogs
Pharmaceutical Preparations
Catheters
Cerebrospinal Fluid
Epidural Injections
Cerebrospinal Fluid Proteins
Tachypnea
Spinal Injections
Clinical Chemistry
Bradycardia
Respiratory Rate
Hypothermia
Canidae
Spinal Cord
Animal Models
Pharmacokinetics
Perfusion

Keywords

  • Analgesics, spinal opioid: alfentanil; morphine; sufentanil
  • Pharmacokinetics
  • Spinal cord: toxicity

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Sabbe, M. B., Grafe, M., Mjanger, E., Tiseo, P. J., Hill, H. F., & Yaksh, T. L. (1994). Spinal delivery of sufentanil, alfentanil, and morphine in dogs: Physiologic and toxicologic investigations. Anesthesiology, 81(4), 899-920.

Spinal delivery of sufentanil, alfentanil, and morphine in dogs : Physiologic and toxicologic investigations. / Sabbe, M. B.; Grafe, Marjorie; Mjanger, E.; Tiseo, P. J.; Hill, H. F.; Yaksh, T. L.

In: Anesthesiology, Vol. 81, No. 4, 1994, p. 899-920.

Research output: Contribution to journalArticle

Sabbe, MB, Grafe, M, Mjanger, E, Tiseo, PJ, Hill, HF & Yaksh, TL 1994, 'Spinal delivery of sufentanil, alfentanil, and morphine in dogs: Physiologic and toxicologic investigations', Anesthesiology, vol. 81, no. 4, pp. 899-920.
Sabbe, M. B. ; Grafe, Marjorie ; Mjanger, E. ; Tiseo, P. J. ; Hill, H. F. ; Yaksh, T. L. / Spinal delivery of sufentanil, alfentanil, and morphine in dogs : Physiologic and toxicologic investigations. In: Anesthesiology. 1994 ; Vol. 81, No. 4. pp. 899-920.
@article{b74fda3d85bb41dd9b11433e4fbcc0a8,
title = "Spinal delivery of sufentanil, alfentanil, and morphine in dogs: Physiologic and toxicologic investigations",
abstract = "Background: This study examines the behavioral effects and potential neurotoxicity of sufentanil, alfentanil, and morphine after chronic daily epidural (15 day) and intrathecal (28-day) administration in dogs. Methods: Dogs were chronically implanted with a lumbar intrathecal or epidural catheter and received daily injections for 28 or 15 days, respectively, of saline or one of three μ agonists: sufentanil (intrathecal 5, 25, or 50 μg/0.5 ml; epidural 10, 50, or 100 μg/2.0 ml), alfentanil (intrathecal 40 or 400 μg/0.5 ml; epidural 80 or 800 μg/2.0 ml), or morphine (intrathecal 0.5 or 5 mg/0.5 ml; epidural 1 or 10 mg/2.0 ml). Dogs were examined for antinociception (skin twitch) and neurobehavioral changes. When the animals were killed, cisternal cerebrospinal fluid was taken for clinical chemistry, and after perfusion fixation, spinal cord tissue was taken for histologic analysis. Results: Bolus intrathecal and epidural injections of sufentanil, alfentanil and morphine produced dose dependent antinociception, bradycardia, an initial tachypnea followed by a decrease in respiratory rate, hypothermia and somnolence. The order of potency was sufentanil > alfentanil > morphine on all measures. Over the extended period of drug delivery, a loss of response (tolerance) was observed on all measures. No abnormal morphologic or histologic effects were found when comparing the drug and dose groups. An inflammatory reaction secondary to the catheter was found in all animals intrathecal, but not epidural, catheters resulted in significant increases in cerebrospinal fluid protein and cell counts in vehicle animals. Values in drug treated animals did not differ significantly from the respective vehicle controls. A rapid systemic redistribution of all three drugs were observed. No differences were found in the pharmacokinetic parameters measured at day 1 and at the day of killing for any route. Conclusions: This large-animal model demonstrates the expected pharmacologic potency of these three agents and tolerance development. Based on cerebrospinal fluid and systematic histopathologic analyses, these three spinally administered agents showed no evidence of neurotoxicity over the range of doses/concentrations employed when given by the intrathecal or epidural route as compared to vehicle controls. Consideration of the toxicokinetics in this canine model suggests that it provides an appropriate test of the safety of these agents in concentrations which exceed those employed for daily intermittent epidural and intrathecal drug delivery in humans.",
keywords = "Analgesics, spinal opioid: alfentanil; morphine; sufentanil, Pharmacokinetics, Spinal cord: toxicity",
author = "Sabbe, {M. B.} and Marjorie Grafe and E. Mjanger and Tiseo, {P. J.} and Hill, {H. F.} and Yaksh, {T. L.}",
year = "1994",
language = "English (US)",
volume = "81",
pages = "899--920",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Spinal delivery of sufentanil, alfentanil, and morphine in dogs

T2 - Physiologic and toxicologic investigations

AU - Sabbe, M. B.

AU - Grafe, Marjorie

AU - Mjanger, E.

AU - Tiseo, P. J.

AU - Hill, H. F.

AU - Yaksh, T. L.

PY - 1994

Y1 - 1994

N2 - Background: This study examines the behavioral effects and potential neurotoxicity of sufentanil, alfentanil, and morphine after chronic daily epidural (15 day) and intrathecal (28-day) administration in dogs. Methods: Dogs were chronically implanted with a lumbar intrathecal or epidural catheter and received daily injections for 28 or 15 days, respectively, of saline or one of three μ agonists: sufentanil (intrathecal 5, 25, or 50 μg/0.5 ml; epidural 10, 50, or 100 μg/2.0 ml), alfentanil (intrathecal 40 or 400 μg/0.5 ml; epidural 80 or 800 μg/2.0 ml), or morphine (intrathecal 0.5 or 5 mg/0.5 ml; epidural 1 or 10 mg/2.0 ml). Dogs were examined for antinociception (skin twitch) and neurobehavioral changes. When the animals were killed, cisternal cerebrospinal fluid was taken for clinical chemistry, and after perfusion fixation, spinal cord tissue was taken for histologic analysis. Results: Bolus intrathecal and epidural injections of sufentanil, alfentanil and morphine produced dose dependent antinociception, bradycardia, an initial tachypnea followed by a decrease in respiratory rate, hypothermia and somnolence. The order of potency was sufentanil > alfentanil > morphine on all measures. Over the extended period of drug delivery, a loss of response (tolerance) was observed on all measures. No abnormal morphologic or histologic effects were found when comparing the drug and dose groups. An inflammatory reaction secondary to the catheter was found in all animals intrathecal, but not epidural, catheters resulted in significant increases in cerebrospinal fluid protein and cell counts in vehicle animals. Values in drug treated animals did not differ significantly from the respective vehicle controls. A rapid systemic redistribution of all three drugs were observed. No differences were found in the pharmacokinetic parameters measured at day 1 and at the day of killing for any route. Conclusions: This large-animal model demonstrates the expected pharmacologic potency of these three agents and tolerance development. Based on cerebrospinal fluid and systematic histopathologic analyses, these three spinally administered agents showed no evidence of neurotoxicity over the range of doses/concentrations employed when given by the intrathecal or epidural route as compared to vehicle controls. Consideration of the toxicokinetics in this canine model suggests that it provides an appropriate test of the safety of these agents in concentrations which exceed those employed for daily intermittent epidural and intrathecal drug delivery in humans.

AB - Background: This study examines the behavioral effects and potential neurotoxicity of sufentanil, alfentanil, and morphine after chronic daily epidural (15 day) and intrathecal (28-day) administration in dogs. Methods: Dogs were chronically implanted with a lumbar intrathecal or epidural catheter and received daily injections for 28 or 15 days, respectively, of saline or one of three μ agonists: sufentanil (intrathecal 5, 25, or 50 μg/0.5 ml; epidural 10, 50, or 100 μg/2.0 ml), alfentanil (intrathecal 40 or 400 μg/0.5 ml; epidural 80 or 800 μg/2.0 ml), or morphine (intrathecal 0.5 or 5 mg/0.5 ml; epidural 1 or 10 mg/2.0 ml). Dogs were examined for antinociception (skin twitch) and neurobehavioral changes. When the animals were killed, cisternal cerebrospinal fluid was taken for clinical chemistry, and after perfusion fixation, spinal cord tissue was taken for histologic analysis. Results: Bolus intrathecal and epidural injections of sufentanil, alfentanil and morphine produced dose dependent antinociception, bradycardia, an initial tachypnea followed by a decrease in respiratory rate, hypothermia and somnolence. The order of potency was sufentanil > alfentanil > morphine on all measures. Over the extended period of drug delivery, a loss of response (tolerance) was observed on all measures. No abnormal morphologic or histologic effects were found when comparing the drug and dose groups. An inflammatory reaction secondary to the catheter was found in all animals intrathecal, but not epidural, catheters resulted in significant increases in cerebrospinal fluid protein and cell counts in vehicle animals. Values in drug treated animals did not differ significantly from the respective vehicle controls. A rapid systemic redistribution of all three drugs were observed. No differences were found in the pharmacokinetic parameters measured at day 1 and at the day of killing for any route. Conclusions: This large-animal model demonstrates the expected pharmacologic potency of these three agents and tolerance development. Based on cerebrospinal fluid and systematic histopathologic analyses, these three spinally administered agents showed no evidence of neurotoxicity over the range of doses/concentrations employed when given by the intrathecal or epidural route as compared to vehicle controls. Consideration of the toxicokinetics in this canine model suggests that it provides an appropriate test of the safety of these agents in concentrations which exceed those employed for daily intermittent epidural and intrathecal drug delivery in humans.

KW - Analgesics, spinal opioid: alfentanil; morphine; sufentanil

KW - Pharmacokinetics

KW - Spinal cord: toxicity

UR - http://www.scopus.com/inward/record.url?scp=0028077279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028077279&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 899

EP - 920

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 4

ER -